AR and melanoma: Based on our identification of this androgen- and fucosylation-regulated molecular mechanism underlying clinical discrepancies associated with male melanoma patients, our study provides compelling preclinical support for the concept of treating melanomas using AR antagonists (e.g., those approved for treating prostate cancer18) as well as for the implementation of androgen- and fucosylation-based biomarkers for potential therapeutic stratification of melanoma patients.